News

Falayi receives SIU Dissertation Research Assistant Award

SIU School of Medicine has recognized Oluwatosin Falayi with a Dissertation Research Assistantship Award for the 2025–26 academic year for her scholarly excellence.
News

Falayi receives SIU Dissertation Research Assistant Award

SIU School of Medicine has recognized Oluwatosin Falayi with a Dissertation Research Assistantship Award for the 2025–26 academic year for her scholarly excellence.
News

Falayi receives SIU Dissertation Research Assistant Award

SIU School of Medicine has recognized Oluwatosin Falayi with a Dissertation Research Assistantship Award for the 2025–26 academic year for her scholarly excellence.
News

The circadian codebreaker

Dr. Shelley Tischkau has spent her career as a sleep detective, meticulously piecing together the intricate relationship between our internal clocks and overall health.
News

The circadian codebreaker

Dr. Shelley Tischkau has spent her career as a sleep detective, meticulously piecing together the intricate relationship between our internal clocks and overall health.
News

The circadian codebreaker

Dr. Shelley Tischkau has spent her career as a sleep detective, meticulously piecing together the intricate relationship between our internal clocks and overall health.
News

The circadian codebreaker

Dr. Shelley Tischkau has spent her career as a sleep detective, meticulously piecing together the intricate relationship between our internal clocks and overall health.
News

The circadian codebreaker

Dr. Shelley Tischkau has spent her career as a sleep detective, meticulously piecing together the intricate relationship between our internal clocks and overall health.
Trial
Neurology

Renaissance 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures

Active recruiting

To evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.

Trial
Simmons Cancer Institute

ASND0029 "IL Believe": A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in

Active recruiting
This study is investigating experimental drugs TransCon IL-2 β/γ and TransCon TLR7/8 for the treatment of advanced/metastatic solid tumors (melanoma, breast cancer, cervical cancer, ovarian cancer) in adults.
Subscribe to Research